ストックスクリーナーアプリを入手
4.58
10.90%
0.45
アフターアワーズ：
4.51
-0.07
-1.53%
前日終値:
$4.13
開ける：
$4.22
24時間の取引高:
3.14M
Relative Volume:
1.15
時価総額：
$1.32B
収益：
$9.77M
当期純損益:
$-109.00M
株価収益率:
-12.71
EPS:
-0.3604
ネットキャッシュフロー:
$-93.83M
1週間 パフォーマンス:
+2.92%
1か月 パフォーマンス:
-1.93%
6か月 パフォーマンス:
+49.67%
1年 パフォーマンス:
+158.76%
1日の値動き範囲:
$4.20
$4.59
1週間の範囲:
$4.075
$4.66
52週間の値動き範囲:
$1.05
$6.02
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
名前
Taysha Gene Therapies Inc
セクター
電話
(214) 612-0000
住所
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
4.58 | 1.19B | 9.77M | -109.00M | -93.83M | -0.3604 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Raymond James | Strong Buy |
| 2025-07-11 | 開始されました | BofA Securities | Buy |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-04-09 | 開始されました | Piper Sandler | Overweight |
| 2023-02-01 | ダウングレード | Jefferies | Buy → Hold |
| 2023-01-27 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-09 | ダウングレード | Goldman | Buy → Neutral |
| 2022-03-09 | 開始されました | Robert W. Baird | Outperform |
| 2022-03-01 | 開始されました | Wells Fargo | Overweight |
| 2022-02-18 | 開始されました | SMBC Nikko | Outperform |
| 2021-12-16 | 開始されました | Guggenheim | Buy |
| 2021-07-16 | 開始されました | Needham | Buy |
| 2021-06-24 | 開始されました | Truist | Buy |
| 2021-06-15 | 開始されました | BTIG Research | Buy |
| 2021-06-09 | 開始されました | Wedbush | Outperform |
| 2021-06-08 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-05-19 | 開始されました | Cantor Fitzgerald | Overweight |
| 2021-05-11 | 再開されました | Jefferies | Buy |
| 2021-02-24 | 開始されました | William Blair | Outperform |
| 2021-01-05 | 開始されました | Oppenheimer | Outperform |
| 2020-10-19 | 開始されました | Chardan Capital Markets | Buy |
| 2020-10-19 | 開始されました | Goldman | Buy |
| 2020-10-19 | 開始されました | Jefferies | Buy |
| 2020-10-19 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Taysha Gene Therapies Inc (TSHA) 最新ニュース
Panic Selling: Whats the fair value of Taysha Gene Therapies Inc stockCEO Change & Technical Entry and Exit Alerts - baoquankhu1.vn
Levels Update: Whats the fair value of Taysha Gene Therapies Inc stock2026 Winners & Losers & AI Powered Trade Plan Recommendations - baoquankhu1.vn
Taysha Gene Therapies (NASDAQ:TSHA) Trading Up 8.5%Should You Buy? - MarketBeat
Cantor Fitzgerald reiterates Overweight on Taysha Gene Therapies stock By Investing.com - Investing.com Canada
Cantor Fitzgerald Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Maintains Target Price $19 - Moomoo
Taysha Gene Therapies (NASDAQ:TSHA) Trading Down 6.9%Time to Sell? - MarketBeat
Taysha outlines 2026 BLA submission path for TSHA-102 as pivotal trial enrollment advances - MSN
How FDA Breakthrough Status For TSHA-102 At Taysha Gene Therapies (TSHA) Has Changed Its Investment Story - Yahoo Finance
Taysha Gene Therapies Receives 'Moderate Buy' Rating from Analysts - National Today
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus - Sahm
Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Chardan Capital Maintains Taysha Gene Therapies (TSHA) Buy Recommendation - MSN
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2025 Earnings Call Transcript - Insider Monkey
Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $12.00 at Needham & Company LLC - MarketBeat
Decoding Taysha Gene Therapies Inc (TSHA): A Strategic SWOT Insi - GuruFocus
Taysha Gene Therapies Q4 Loss Of US$27.9m Tests Bullish TSHA 102 Narrative - simplywall.st
Taysha Gene Therapies Signals Momentum in Earnings Call - TipRanks
Taysha Gene Therapies (TSHA) Advances Rett Syndrome Treatment - GuruFocus
Jefferies raises Taysha Gene Therapies price target on trial progress By Investing.com - Investing.com Canada
Key facts: Taysha $109M loss; Q4 rev +171%; $320M cash; TSHA-102 safe, Q2'26 - TradingView
TSHA: Analyst Chardan Capital Maintains Buy Rating with $12 PT | - GuruFocus
Chardan Capital Reaffirms "Buy" Rating for Taysha Gene Therapies (NASDAQ:TSHA) - MarketBeat
Raymond James reiterates Strong Buy on Taysha Gene Therapies stock By Investing.com - Investing.com Australia
Taysha Gene Therapies Inc (TSHA) Q4 2025 Earnings Call Highlight - GuruFocus
Taysha Gene Therapies Q4 2025 Earnings Call Transcript - MarketBeat
Taysha Gene Therapies, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Taysha Gene Therapies’ Q4 Earnings Call: FDA Timeline, European Strategy Claims Don’t Match Prior Statements - Bitget
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress i - GuruFocus
Taysha Gene Therapies Q4 Earnings Call Highlights - MarketBeat
Taysha Gene Therapies 2026 Conference Call: TSHA-102 Development & Regulatory PlansNews and Statistics - IndexBox
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update - Investing News Network
TSHA: TSHA-102 advanced toward registration with strong trial data, FDA alignment, and solid cash runway - TradingView
Taysha Gene Therapies (NASDAQ:TSHA) Shares Gap Up After Better-Than-Expected Earnings - MarketBeat
Taysha Gene Therapies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Taysha (TSHA) Fourth Quarter 2025 Earnings Conference Call Transcript - Bitget
Taysha (TSHA) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss - Investing.com India
Earnings call transcript: Taysha Gene Therapies Q4 2025 sees widened loss By Investing.com - Investing.com South Africa
Taysha Gene Therapies (NASDAQ:TSHA) Releases Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Valuation Update: How correlated is Taysha Gene Therapies Inc to the S P5002026 Price Momentum & Daily Oversold Bounce Ideas - baoquankhu1.vn
Taysha Gene Therapies, Inc. Appoints Brad Martin as Senior Vice President, Market Access and Value - marketscreener.com
Taysha (TSHA) Reports Strong Q4 Revenue and Promising Progress in Trials - GuruFocus
Taysha Gene Therapies 10-K: $9.8M Revenue, $(0.34) EPS - TradingView
Rett gene therapy advances at Taysha Gene Therapies (TSHA) - Stock Titan
Taysha Gene Therapies reports full-year 2025 earnings and issues corporate update - Traders Union
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M - marketscreener.com
Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Net Loss $0.34 a Share, vs. FactSet Est of $0.37 Loss - marketscreener.com
Taysha Gene Therap Reports 2025 Full-Year Results — $9.8M Revenue, $109.0M Net Loss - TradingView
Taysha Gene Therapies (TSHA) deepens 2025 loss but advances Rett trial - Stock Titan
TSHA: TSHA-102 trials progressed with strong safety, regulatory alignment, and robust cash position - TradingView
Taysha Gene Therapies Inc (TSHA) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):